The Cancer and Hematology Centers

Grand Rapids, Michigan 49546

4 studies enrolling now · 7 studies all time

What they study most

B Cell Lymphoma, Chronic Lymphocytic Leukemia, Extra-Pancreatic Neuroendocrine Tumor (epNET), HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer, Mantle Cell Lymphoma, Metastatic Uveal Melanoma, Neuroendocrine Carcinomas, Pancreatic Neuroendocrine Tumor (pNET), Small Lymphocytic Lymphoma, Small-cell Lung Cancer, Solid Tumor Show to Express DLL3, Uveal Melanoma

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors — Recruiting now
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) — Recruiting now
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer — Recruiting now
• (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma — Running, not enrolling
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma — Running, not enrolling
• A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer — Completed